Updated:
Sanemus
SANEMUS investiert in Unternehmens- und Vermögensbeteiligungen im Gesundheitsmarkt und bietet Strategic, Financial-, und Merger&Acquisition-Advisory an.
Sanemus
SANEMUS investiert in Unternehmens- und Vermögensbeteiligungen im Gesundheitsmarkt und bietet Strategic, Financial-, und Merger&Acquisition-Advisory an.
General information
Firm type
Private Equity
Year founded
2006
AUM
Undisclosed
Location
Region
Europe
Country
Germany
City
Munich
Corporate office
Munich, Germany
Principals
Michael Thiess
Partner and Board Member
Sonja Hager
Member of Management
Sector focus
Frequently asked questions
What does Sanemus actually own?
The firm website lists three active portfolio companies. ProPharm AG is a cooperative network of 75 independent German pharmacies that bundles purchasing, marketing, and mail-order services. Aureleon Diagnostics GmbH is developing multiplex diagnostic tests for cardiac and oncology applications. 52masterworks GmbH runs a crowd-investing marketplace for contemporary fine art.
Who makes investment decisions at Sanemus?
Michael Thiess leads the investment process in his role as partner and board member. Sonja Hager, a Certified Private Equity Analyst, joined the management board in December 2023 and supports decision-making as the senior investment professional. The three-member supervisory board offers additional governance.
Does Sanemus operate like a traditional venture firm?
No. The company identifies as a private equity firm but does not raise funds from external limited partners. It invests its own balance-sheet capital alongside its advisory business, which generates outside fee revenue from strategic and M&A consulting, blurring the line between a fund manager and a corporate-finance boutique.
What investment stages does Sanemus target?
Altss research tags the firm as active across early-stage start-up, expansion, and growth phases. The portfolio reflects this range: ProPharm was a late-stage service-platform investment, while aureleon diagnostics represents a clinical-stage life-science play.
Which healthcare sub-sectors does Sanemus focus on?
The firm explicitly names pharmaceuticals, biotechnology, medical technology, diagnostics, and e-health. Its pharmaceutical investments center on distribution and margin improvement rather than drug discovery, while the diagnostics exposure targets algorithmic multiplex biomarker analysis.
Does Sanemus participate in fund commitments or only direct deals?
All known investments are direct equity stakes in German operating companies. There is no evidence the firm commits to external private equity or venture funds.
How is the advisory business separated from the investment portfolio?
Both sit inside Sanemus AG. The firm publicly states it offers strategic, financial, and M&A advisory to third parties while managing its own direct investments. Fee income from advisory mandates replenishes the investment pool organically, which means the firm can deploy capital without marketing to external LPs.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: